Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CPX-351 in Elderly Patients With AML
NCT03335267Phase 2Completed
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cytarabine in acute myeloid leukemia (AML), sponsored by Weill Cornell Medicine. Started Oct 2017; status: completed.
02
Drugs
cytarabine
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT03335267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03335267.